-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
HIV-1-inhibitor-47
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/137448-39-6.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 137448-39-6 |
| Description | HIV-1 inhibitor-47 is an inhibitor of HIV-1, and inhibits vif-dependent degradation of human APOBEC3G, with an IC50 value of 14.33 μM. HIV-1 inhibitor-47 also involves in derivatives of 1-(2-pyrimidinyl)piperazine synthesis, with potential antianxiety, antidepressant, and antipsychotic effect. |
Product Information
| Molecular Weight | 242.28 |
| Molecular Formula | C12H14N6 |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | APOBEC3G (A3G), a host cytidine deaminase that can block HIV-1 replication and shows antiviral activity. However HIV-1 develops the ability to hijack the cellular ubiquitin/proteasome degradation pathway. HIV-1 inhibitor-47 targets APOBEC3G-apolipoprotein B mRNA editing enzyme catalytic subunit 3G (human), and works on the HIV-1 Vif-APOBEC3G interaction. |
| Target | HIV (Vif-dependent degradation of human APOBEC3G) |
